Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate maternal medical and perinatal outcomes associated with antipsychotic drug use in pregnancy. DESIGN: High dimensional propensity score (HDPS) matched cohort study. SETTING: Multiple linked population health administrative databases in the entire province of Ontario, Canada. PARTICIPANTS: Among women who delivered a singleton infant between 2003 and 2012, and who were eligible for provincially funded drug coverage, those with ≥ 2 consecutive prescriptions for an antipsychotic medication during pregnancy, at least one of which was filled in the first or second trimester, were selected. Of these antipsychotic drug users, 1021 were matched 1:1 with 1021 non-users by means of a HDPS algorithm. MAIN OUTCOME MEASURES: The main maternal medical outcomes were gestational diabetes, hypertensive disorders of pregnancy, and venous thromboembolism. The main perinatal outcomes were preterm birth (<37 weeks), and a birth weight <3rd or >97th centile. Conditional Poisson regression analysis was used to generate rate ratios and 95% confidence intervals, adjusting for additionally prescribed non-antipsychotic psychotropic medications. RESULTS: Compared with non-users, women prescribed an antipsychotic medication in pregnancy did not seem to be at higher risk of gestational diabetes (rate ratio 1.10 (95% CI 0.77 to 1.57)), hypertensive disorders of pregnancy (1.12 (0.70 to 1.78)), or venous thromboembolism (0.95 (0.40 to 2.27)). The preterm birth rate, though high among antipsychotic users (14.5%) and matched non-users (14.3%), was not relatively different (rate ratio 0.99 (0.78 to 1.26)). Neither birth weight <3rd centile or >97th centile was associated with antipsychotic drug use in pregnancy (rate ratios 1.21 (0.81 to 1.82) and 1.26 (0.69 to 2.29) respectively). CONCLUSIONS: Antipsychotic drug use in pregnancy had minimal evident impact on important maternal medical and short term perinatal outcomes. However, the rate of adverse outcomes is high enough to warrant careful assessment of maternal and fetal wellbeing among women prescribed an antipsychotic drug in pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128
Viguera, A. C., Whitfield, T., Baldessarini, R. J., Newport, D. J., Stowe, Z., Reminick, A., Zurick, A., & Cohen, L. S. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06101639 · Cited by 599
Manifestations of chronic disease during pregnancy
Kaaja, R. J. (2005) · JAMA · doi:10.1001/jama.294.21.2751 · Cited by 382
Validation of a case definition to define hypertension using administrative data
Quan, H., Khan, N., Hemmelgarn, B. R., Tu, K., Chen, G., Campbell, N., Hill, M. D., Ghali, W. A., & McAlister, F. A. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.139279 · Cited by 350
Ross, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.684 · Cited by 268
Boden, R., Lundgren, M., Brandt, L., Reutfors, J., Andersen, M., & Kieler, H. (2012) · BMJ · doi:10.1136/bmj.e7085 · Cited by 245
The relationship between maternal glycemia and perinatal outcome
Landon, M. B., Mele, L., Spong, C. Y., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2011) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318203ebe0 · Cited by 150
Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview
Bellantuono, C., Tofani, S., Di Sciascio, G., & Santone, G. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.09.003 · Cited by 122
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
McAllister-Williams, R. H., Baldwin, D. S., Cantwell, R., Easter, A., Gilvarry, E., Glover, V., Green, L., Gregoire, A., Howard, L. M., Jones, I., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699361 · Cited by 271
Managing Your Own Mood Lability: Use of Mood Stabilizers and Antipsychotics in Pregnancy
Wichman, C. L. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0646-1 · Cited by 258
Assessment of stimulant use and cardiovascular event risks among older adults
Tadrous, M., Shakeri, A., Chu, C., Watt, J., Mamdani, M. M., Juurlink, D. N., & Gomes, T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.30795 · Cited by 49
“14 Moreover, given that the trials consisted of younger adult patients with a median (range) age of 36 (22-40) years, we anticipated a greater increase in risk associated with the prevalence of comorbidities among an older population.”
BackgroundSelf-citation
Metadata
- Authors
- Vigod, S. N., Gomes, T., Wilton, A. S., Taylor, V. H., & Ray, J. G.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2015-05-13
- Volume
- 350
- Issue
- may11 5
- Pages
- h2298-h2298
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2141081839
- Cited by
- 162
- References
- 10
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.